Shandong Boan Wins China Approval to Begin BA2201 Clinical Trials

PUBT · 4d ago
Shandong Boan Wins China Approval to Begin BA2201 Clinical Trials
  • Shandong Boan Biotechnology received Chinese regulatory clearance to begin clinical trials of BA2201, its TL1A/IL-23 bispecific antibody for inflammatory bowel disease.
  • The Phase 1/2a trial will evaluate subcutaneous BA2201 in healthy participants and patients with moderate to severe active ulcerative colitis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261106-12403309), on November 06, 2026, and is solely responsible for the information contained therein.